Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1406 2 vs 3 Injections in Healthy Participants
NCT07743151Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of retezrelvir (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration Time Curve From Time 0 to 4 Weeks, Number of Participants Who Experience One or More Adverse Events at 43 days and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
retezrelvir
Beyond the preview
Go deeper on NCT07743151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743151.